US Patent 8129167 UL16 binding protein 4
Patent 8129167 was granted and assigned to Immunex on March, 2012 by the United States Patent and Trademark Office.
All edits
Edits on 1 Feb, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 12 Jan, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 28 Nov, 2023
Golden AI
Edits made to:
Article (+253 characters)
Article
Patent abstract
ULBP4, a novel member of the ULBP family has been isolated and characterized. ULBP4 is a useful activator of immune effector cells, particularly of NK cells. Nucleic acids encoding ULBP4, vectors, and cells encoding the same are provided.
Edits on 15 Jul, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 08129167 UL16 binding protein 4 US Patent 8129167 UL16 binding protein 4
Infobox
Patent Number
0812916700
Patent Number
812916700
Edits on 26 Apr, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
081291670
Date of Patent
March 6, 2012
0Patent Application Number
124795430
Date Filed
June 5, 2009
0Patent Primary Examiner
Edits on 23 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
081291670
Date of Patent
March 6, 2012
0Patent Application Number
124795430
Date Filed
June 5, 2009
0Patent Primary Examiner
Edits on 14 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 08129167 UL16 binding protein 4
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
08129167
Date of patent
March 6, 2012
Patent application number
12479543
Date Filed
June 5, 2009
Patent primary examiner
Find more entities like US Patent 8129167 UL16 binding protein 4
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
